- Patterns of Neutropenia and Risk Factors for Febrile Neutropenia of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP
-
Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, Jin UR, Park JS
- KMID: 2069930
- J Korean Med Sci.
- 2014 Nov;29(11):1493-1500.
- doi: 10.3346/jkms.2014.29.11.1493
Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL). The prediction of neutropenia... -
- CITED
-
- Close
- SHARE
-
- Close
- Late-onset Neutropenia Following Rituximab Therapy as a Treatment of Diffuse Large B-cell Lymphoma: A Single Institution Study
-
Kim M, Lee JK, Hong YJ, Hong SI, Kang HJ, Chang YH
- KMID: 1781661
- Korean J Lab Med.
- 2010 Dec;30(6):575-579.
- doi: 10.3343/kjlm.2010.30.6.575
BACKGROUND: Late-onset neutropenia (LON) following rituximab therapy has been reported in recent years. However, its incidence has not been reported in Korea. The aim of this study is to investigate... -
- CITED
-
- Close
- SHARE
-
- Close
